MetLife Investment Management’s CureVac CVAC Stock Holding History

MetLife Investment Management’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,437	Closed	-$67.4K	–	2872
2022 Q1	$67.4K	Buy	+3,437	New	+$68.6K	﹤0.01%	2658

Other funds holding CVAC

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

MetLife Investment Management's CVAC Position: Q2 2022 in Review

MetLife Investment Management sold out of CureVac (CVAC) in Q2 2022, closing a stake of 3,437 shares — an estimated $67.4K sold.

MetLife Investment Management first reported a position in CVAC in Q1 2022 and held it in 1 quarter. The position peaked at $67.4K in Q1 2022. 88 funds tracked by Wall St. Rank hold CVAC as of Q2 2022.

MetLife Investment Management reported no remaining CureVac position as of Q2 2022 after selling out during the quarter.
MetLife Investment Management sold 3,437 CureVac shares in Q2 2022, an estimated $67.4K.
MetLife Investment Management first reported a position in CureVac in Q1 2022 and held it in 1 quarter.
MetLife Investment Management's CureVac position peaked at $67.4K in Q1 2022.
88 funds tracked by Wall St. Rank held CureVac as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.